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Background
Imaging studies of Major Depression Disorder (MDD) 
have shown hyperactivation of amygdala and 
differences in its reactivity to emotional stimuli.
However, volumetric findings are much more 
heterogeneous [1]. Two potencial reasons are:
  * Most of the studies do not discriminate     
     patients with distinct long-term outcomes.
  * Other structural characteristics apart from 
     volume could exist.
The aim of this study is to analyze shape and 
volume differences of amygdala in patients with 
different amd well-defined illness stages of MDD. 
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Results
ANOVA did not show significant differences nor in 
left (F(3,21)=0.78, p=0.5) or in right (F(3,121)=0.89, 
p=0.45) ICV-normalized amygdala volumes. (Table 1)
FIRST analyzes indicated shape differences in right 
basolateral amygdala (ventral nucleus and the most  
connected with the cortex). p<0.05, cluster corrected. 
(Figure 1) 
Table 1. Demographics and amygdala volumes (mm3) of four groups. 
Means, standard deviations and ratios are provided. 
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Participants underwent an MRI (3-Tesla):
Structural MRI processing:
 Volume - Left and right amygdala were segmented 
    (Freesurfer v5), and size normalized to total 
    intracranial volume (ICV).
 Shape - FIRST (model-based 
    segmentation/registration tool) 
    of FSL was used.    
Statistics - ANOVA of 4 groups:  
 Volume= SPSS   
 Shape= Vertex analysis (FIRST - FSL5)
Age and gender were introduced as covariates 
when necessary.
Healthy controls showed 
shape differences 
compared to remited-
recurrent  patients (A) and 
to treament-resistant  
patients (B). 
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Figure 1. Coronal views of T1-MPRAGE images showing shape 
differences in right amygdala (coloured voxels).    
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Conclusions
There are structural alterations of the 
amygdala in advanced stages of MDD.
As these alterations are not present in early 
stages of the illness, amygdala could be 
suffering morphological changes as a result 
of a long-term dysfunction of the emotional 
processing circuit [2].
These findings agree with the seminal hyphotesis 
of structural volum losses of amygdala and 
hippocampus as a consequence of 
glucocorticoid-induced neurotoxicity [3].
Basolateral amygdala is crucial in the expression 
and regulation of emotion.
A longitudinal study would truly respond 
whether these differences are a consequence of 
the disease. 
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  62 healthy controls
  25 first-episode
  22 remitted-recurrent 
  21 treatment-resistant
